



[Home](#) [About us](#) [Contact us](#) [Subscribe](#) [For Authors](#) [For Advertisers](#)

Login Here

Email

Password

Remember Me

[Register](#)

Search

The Magazine

[Featured Subjects/Topics](#)

[Product News](#)

[Industry News](#)

[Current Issue](#)

[Next Issue](#)

[Past Issues](#)

[Interviews](#)

[Show Previews](#)


[Testimonials](#)

[Company Listings A-Z](#)

[Online Marketing Opportunities](#)

[Article Reprints](#)

[EPDR issue 1/09](#)



Emerging Superpowers of Clinical Research - Ru

Latest News

[£1 million boost for synthetic chemistry research at the University of East Anglia](#)

Scientists at the University of East Anglia (UEA) have been awarded £1 million to expand their groundbreaking work on synthetic organic chemistry...

[read more](#)

Editor's Corner



[Thanks to all involved with Cellular Imaging Analysis 2009 . .](#)

As you may know we held our first event at the beginning of February in collaboration with the Institute of Molecular Medicine at Trinity College Dublin. I want to take this opportunity to thank those of you who made it along and for all your kind words of support after the event. I felt the event went really well and we are now beginning to work on the next European Pharmaceutical Conference so keep checking out our site.

Issue 2 is out this month which will include variety of articles as always, plus we are including our first ever Stem Cells Roundtable. Several experts are taking part in the roundtable one of which is Dr Stephen Minger from King's College London. Stephen is a Senior Lecturer and Director of King's Stem Cell Biology Laboratory and has provided a varied and interesting point of view to our roundtable.

I hope you have all had the chance to look at

[Novoxel Strengthens its Scientific Advisory Board with the Appointment of Dr. Karen Bush](#)

Novoxel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB)...

[read more](#)

[BioMedPartners strengthens its management team](#)

BioMedPartners, one of Europe's leading healthcare venture capital firms, has further strengthened its management team with the addition of Dr. Andreas J. Schulze and the promotion of Patrick Burgermeister...

[read more](#)

[Rexahn Pharmaceuticals, Inc. \(RNN\) Initiates Phase II Pancreatic Cancer Clinical Trial](#)

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a leader in development of innovative therapeutics for life-threatening

out now!**Events****Our Events****Industry Events****ELRIG Conference****For Advertisers****Advert Specifications****Contact Sales****Industry Focus 2010****Media Pack****For Authors****Become a Contributor****Contact Editorial****Editorial Calendar****Notes for Authors**

and life-debilitating diseases, announced that it has received FDA approval to begin Phase II trials for Archexin™, the Company's leading cancer compound, for the treatment of pancreatic cancer...
[read more](#)

our latest Digital offering but if not, take a [look here](#).

Interested in contributing editorial?

If you have an interesting project that you would like to share with our readers, please contact me, I'd love to hear from you.

[Email me](#)

A decade on, but not NICE for cancer patients

Cancer experts say major flaws in the system for approving drugs are still leaving the latest treatments under-used in the NHS...
[read more](#)

Covance Completes Major Biosafety Expansion, Doubles Biotechnology Service Capacity in Europe and Receives cGMP Manufacturing License

Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, announced the completion of an additional 8,000-sq. ft. to its biotechnology services facility in Harrogate, UK...
[read more](#)

[>>Read more news stories](#)



Russell Publishing Ltd
Court Lodge
Hogtrough Hill
Brasted
Kent TN16 1NU. UK
Registered in England
No. 2709148
Registered office as above.
VAT No. GB 577 897847

Our top 5 articles from the latest issue**miRNA and viral infections in vertebrates**

Pål Sætrom, Post Doctoral Fellow, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology and Jörn Klein, Post Doctoral Fellow, Department of Computer and Information Science, Norwegian University of Science and Technology

[Read article in full](#)

Article 1: the importance of sample quality for qPCR

Tania Nolan, Global Manager, Sigma-Aldrich and Stephen Bustin, Professor of Molecular Science, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry

[Read article in full](#)

High Content Analysis approach for targeted gene silencing and probing nanoscale cell responses

Dr Aideen Long, Senior Lecturer and Professor Yuri Volkov, Associate Professor of Molecular Medicine, Trinity College Dublin

[Read article in full](#)

Progress by the Proteomics Standards Initiative

Dr Chris Taylor, Senior Software Engineer and Lennart Martens, Group Co-ordinator of Proteomics Services, European Bioinformatics Institute

[Read article in full](#)

Raman spectroscopic techniques for biotechnology and bio-processing**Dates for your diary****»Cambridge Healthtech Institutes Drug Discovery Chemistry**

Date: 6-7 April 09 **Location:** California
[more info](#)

»Advances in Synthetic Chemistry

Date: 16-17 April 09 **Location:** Scotland, UK
[more info](#)

»Advances in Synthetic Biology

Date: 28-29 April 09 **Location:** London, UK
[more info](#)

»5th High Throughput Medicinal Chemistry Conference

Date: 12 May 2009
Location: Cheshire, UK
[more info](#)

»DxRx Summit

Date: 12-13 May 2009
Location: Boston, MA, USA
[more info](#)

Victoria Brewster, PhD Student, Roger Jarvis, Research Assistant and Royston Goodacre, Professor of Biological Chemistry, University of Manchester

[Read article in full](#)

If you would like to view the latest issue in full, please click [here](#)



We are delighted to partner the Royal United Services Institute with their conference, Critical National Infrastructure. Many readers will understand and take responsibility for business continuity. In our increasingly just-in-time so country's reliance on it's CNI has continued to grow and our dependence is now such that even fleeting disrupt potentially disastrous.

[Click here for further details.](#)

[Contact](#) [Sitemap](#) [Login](#) [Join Now](#) [RSS](#) [Terms & Conditions](#) [Privacy Po](#)
Copyright 2000-2008 Russell Publishing Limited - Powered by [SubHub](#) - [Membership Websi](#)